CTRI/2021/10/037418尚未招募1 期
Development of an EORTC module for renal cancer patients: phase I-II - EORTC RCC
Innsbruck Medical University0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Inclusion Criteria for the patients:
- •1.Patients with a diagnosis of renal cell cancer (irrespective of treatment or follow up status)
- •2.Patients who are18 years of age or above
- •3.Patients with no other concurrent malignancies
- •4.Patients with no cognitive impairment
- •5.Patients willing to provide written informed consent for the study
- •Inclusion criteria for HCPs:
- •1.Consultants from any of the specialist disciplines of medical oncology, surgical oncology, other (radiation oncology) treating patients with RCC
- •2.Consultants of either gender
- •3.Willing to participate and provide a written informed consent
排除标准
- •Exclusion criteria for patients:
- •1.None. Anyone fulfilling the inclusion criteria will be eligible for the study.
- •Exclusion criteria for HCPs:
- •1.None. Anyone fulfilling the inclusion criteria will be eligible for the study
- •2.Patients not willing to provide written informed consent
研究者
相似试验
Unknown
不适用
TRACERx Renal CAPTURE Sub-studyHealthy VolunteersCancerRenal Cell CarcinomaNCT03226886Royal Marsden NHS Foundation Trust360
招募中
3 期
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyClear Cell Renal Cell CarcinomaNCT06750419Telix Pharmaceuticals (Innovations) Pty Limited82
招募中
不适用
Development of software that predicts the response of chemotherapy in colorectal and head and neck cancers through artificial intelligenceCTRI/2022/10/046397BIRAC
已完成
3 期
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyClear Cell Renal Cell CarcinomaNCT03849118Telix Pharmaceuticals (Innovations) Pty Limited300
招募中
不适用
SABR for Renal TumorsRenal TumorNCT03747133University Health Network, Toronto90
